Steve Vucic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6378692/publications.pdf

Version: 2024-02-01

74 papers	6,225 citations	117625 34 h-index	88630 70 g-index
74 all docs	74 docs citations	74 times ranked	5852 citing authors

#	Article	IF	Citations
1	Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2022, 65, 43-50.	2.2	6
2	Chronic inflammatory demyelinating polyneuropathy after commencement of dupilumab for atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2022, 128, 105-106.	1.0	3
3	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 321-328.	1.7	4
4	The split-elbow index: A biomarker of the split elbow sign in ALS. Clinical Neurophysiology Practice, 2022, 7, 16-20.	1.4	4
5	Long read sequencing overcomes challenges in the diagnosis of <scp>SORD</scp> neuropathy. Journal of the Peripheral Nervous System, 2022, 27, 120-126.	3.1	6
6	Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 668-678.	1.9	35
7	Electrodiagnostic findings in facial onset sensory motor neuronopathy (FOSMN). Clinical Neurophysiology, 2022, 140, 228-238.	1.5	2
8	Pathophysiological associations of transcallosal dysfunction in ALS. European Journal of Neurology, 2021, 28, 1172-1180.	3.3	12
9	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95.	1.9	174
10	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
11	Neurotoxicity and ALS: Insights into Pathogenesis. , 2021, , 1-19.		0
12	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open, 2021, 11, e041479.	1.9	33
13	Diagnostic Utility of Gold Coast Criteria in <scp>Amyotrophic Lateral Sclerosis</scp>. Annals of Neurology, 2021, 89, 979-986.	5.3	68
14	Advances in the understanding of sensory neuronopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 343-343.	1.9	0
15	P300 jitter latency, brain-computer interface and amyotrophic lateral sclerosis. Clinical Neurophysiology, 2021, 132, 614-615.	1.5	1
16	Association of Cortical Hyperexcitability and Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis. Neurology, 2021, 96, e2090-e2097.	1.1	12
17	Utility of Transcranial Magnetic Simulation in Studying Upper Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis. Brain Sciences, 2021, 11, 906.	2.3	4
18	The Upper Motor Neuronâ€"Improved Knowledge from ALS and Related Clinical Disorders. Brain Sciences, 2021, 11, 958.	2.3	3

#	Article	IF	Citations
19	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1126-1130.	1.9	25
20	Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment. Muscle and Nerve, 2021, 64, 532-537.	2.2	16
21	Review Article â€œSpotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Dateâ€. International Journal of General Medicine, 2021, Volume 14, 4579-4604.	1.8	7
22	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. Annals of Clinical and Translational Neurology, 2021, 8, 1991-1999.	3.7	18
23	Nerve biopsy in acquired neuropathies. Journal of the Peripheral Nervous System, 2021, 26 Suppl 2, S21-S41.	3.1	2
24	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	2.2	13
25	Measurement of axonal excitability: Consensus guidelines. Clinical Neurophysiology, 2020, 131, 308-323.	1.5	63
26	Split-hand sign: clinical feature of spinal bulbar muscular atrophy?. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1143-1144.	1.9	0
27	ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology, 2020, 94, e1657-e1663.	1.1	39
28	Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study). Medicine (United States), 2020, 99, e18904.	1.0	23
29	Reproducibility of motor unit number index and MScanFit motor unit number estimation across intrinsic hand muscles. Muscle and Nerve, 2020, 62, 192-200.	2.2	17
30	Cortical hyperexcitability evolves with disease progression in ALS. Annals of Clinical and Translational Neurology, 2020, 7, 733-741.	3.7	45
31	Regional motor cortex dysfunction in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 1373-1382.	3.7	19
32	Amyotrophic lateral sclerosis as a multi-step process: an Australia population study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 532-537.	1.7	22
33	Split elbow sign: more evidence for the importance of cortical dysfunction in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 729-729.	1.9	10
34	Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2018, 75, 681.	9.0	120
35	Inter-session reliability of short-interval intracortical inhibition measured by threshold tracking TMS. Neuroscience Letters, 2018, 674, 18-23.	2.1	34
36	Physiological changes in neurodegeneration â€” mechanistic insights and clinical utility. Nature Reviews Neurology, 2018, 14, 259-271.	10.1	72

#	Article	IF	Citations
37	Neurofascinâ€155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. Muscle and Nerve, 2018, 57, 848-851.	2.2	37
38	Utility of threshold tracking transcranial magnetic stimulation in ALS. Clinical Neurophysiology Practice, 2018, 3, 164-172.	1.4	51
39	Imbalance of cortical facilitatory and inhibitory circuits underlies hyperexcitability in ALS. Neurology, 2018, 91, e1669-e1676.	1.1	67
40	Physiological Processes Underlying Short Interval Intracortical Facilitation in the Human Motor Cortex. Frontiers in Neuroscience, 2018, 12, 240.	2.8	31
41	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. Clinical Neurophysiology, 2018, 129, 2162-2169.	1.5	15
42	Functional Biomarkers for Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1141.	2.4	23
43	The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2017, 128, 1075-1082.	1.5	34
44	Motor neurone disease: progress and challenges. Medical Journal of Australia, 2017, 206, 357-362.	1.7	28
45	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open, 2016, 6, e012054.	1.9	48
46	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. Clinical Neurophysiology, 2016, 127, 2684-2691.	1.5	74
47	Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nature Reviews Neurology, 2016, 12, 651-661.	10.1	165
48	Diagnostic criteria in amyotrophic lateral sclerosis. Neurology, 2016, 87, 684-690.	1.1	46
49	Motor cortical function determines prognosis in sporadic ALS. Neurology, 2016, 87, 513-520.	1.1	76
50	Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2016, 16, 1147-1154.	2.8	22
51	Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 580-588.	1.7	58
52	Rate of disease progression: a prognostic biomarker in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 628-632.	1.9	123
53	Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurology, The, 2015, 14, 478-484.	10.2	164
54	Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. Journal of Neurology, 2015, 262, 1424-1432.	3.6	47

#	Article	IF	Citations
55	Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clinical Neurophysiology, 2015, 126, 803-809.	1.5	140
56	Cortical Dysfunction Underlies the Development of the Split-Hand in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e87124.	2.5	75
57	Cortical hyperexcitability and the split-hand plus phenomenon: Pathophysiological insights in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 250-256.	1.7	27
58	Cortical excitability differences in hand muscles follow a splitâ€hand pattern in healthy controls. Muscle and Nerve, 2014, 49, 836-844.	2.2	22
59	ALS pathophysiology: Insights from the split-hand phenomenon. Clinical Neurophysiology, 2014, 125, 186-193.	1.5	44
60	Split-hand plus sign in ALS: Differential involvement of the flexor pollicis longus and intrinsic hand muscles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 315-318.	1.7	46
61	Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2013, 124, 410-416.	1.5	97
62	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain, 2013, 136, 1361-1370.	7.6	123
63	FOSMN syndrome. Neurology, 2012, 79, 73-79.	1.1	47
64	Cortical excitability distinguishes ALS from mimic disorders. Clinical Neurophysiology, 2011, 122, 1860-1866.	1.5	122
65	Amyotrophic lateral sclerosis. Lancet, The, 2011, 377, 942-955.	13.7	2,182
66	Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 33-38.	2.1	47
67	Upregulation of persistent sodium conductances in familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 222-227.	1.9	86
68	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 2010, 133, 2727-2733.	7.6	29
69	Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 2008, 131, 1540-1550.	7.6	391
70	Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology, 2007, 69, 1828-1835.	1.1	27
71	Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 849-852.	1.9	97
72	Assessment of cortical excitability using threshold tracking techniques. Muscle and Nerve, 2006, 33, 477-486.	2.2	162

#	Article	IF	Citations
73	Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain, 2006, 129, 2436-2446.	7.6	284
74	Autosomal recessive hereditary spastic paraparesis with thin corpus callosum; report of two sisters. Journal of Clinical Neuroscience, 2004, 11, 427-430.	1.5	4